<unk>  is a Monoclonal antibodies that is FDA approved for the treatment of neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME).   Common adverse reactions include cataract, conjunctival hemorrhage, eye irritation, foreign body sensation, in the eyes, inflammatory disorder of the eye, pain in eye, raised intraocular pressure, visual disturbance, vitreous detachment, vitreous floaters.
Ranibizumab
Ruxolitinib
Gilteritinib
Erdafitinib
Avelumab
Pazopanib hydrochloride
Baricitinib
Alirocumab